Modified Platelet Delivery of Checkpoint Inhibitors for AML
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) are inadequate, with traditional chemotherapy providing incomplete remission and significant side effects, and CAR-T cell therapy being costly and associated with adverse reactions, necessitating a more effective and safer approach for leukemia cell elimination.
Innovation Solution
Development of therapeutic agent delivery vehicles using modified platelets conjugated with immune checkpoint inhibitors, such as PD-1 inhibitors, to target and deliver therapeutic agents directly to the bone marrow, enhancing immune response and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy is used to treat AML, then leukemia cells can be eliminated to some extent, but the remission is incomplete and side effects occur
Solution Approach 1:
The invention segments the therapeutic approach by using modified platelets as individual delivery vehicles that specifically target bone marrow leukemia cells, rather than using systemic chemotherapy that affects all rapidly dividing cells. This segmentation allows the therapeutic agent to be delivered precisely to the target site, improving remission completeness while reducing off-target side effects.
Solution Approach 2:
The invention introduces modified platelets as intermediary carriers between the therapeutic agent and the leukemia cells. These platelets are modified to express targeting moieties that recognize bone marrow leukemia cells, serving as a mediator that delivers the therapeutic agent specifically to the target cells while avoiding non-specific toxicity to healthy tissues.
2Reliability
If CAR-T cell therapy is used to treat AML, then treatment outcomes are impressive, but the cost is high and adverse reactions occur
Solution Approach 1:
The invention uses modified platelets as disposable, short-lived delivery vehicles that can be administered systemically and then naturally cleared by the body. These platelets are modified in vitro with targeting moieties and therapeutic agents, then administered as a one-time treatment rather than requiring long-term engineered living cells like CAR-T, reducing both complexity and cost while maintaining effectiveness.
Solution Approach 2:
The invention replaces the complex biological engineering system of CAR-T cells (which requires genetic modification, cell culture, and in vivo persistence) with a simpler in vitro modified platelet system that delivers therapeutic agents and then is naturally cleared. This substitution reduces treatment complexity and cost while maintaining the ability to specifically target and eliminate leukemia cells.
3Reliability
If hematopoietic stem cell transplantation is used to treat relapsed leukemia, then cure is possible, but mortality is high due to infections and graft-versus-host disease
Solution Approach 1:
The invention extracts the essential function of stem cell transplantation (eliminating leukemia cells) while removing the harmful aspects (immune reconstitution, graft-versus-host disease risk). By using modified platelets to deliver therapeutic agents directly to leukemia cells, the treatment achieves leukemia cell elimination without requiring immunosuppression or risk of graft-versus-host disease.
Solution Approach 2:
The invention converts the natural physiological role of platelets (which are normally involved in clotting and can cause thrombotic complications) into a beneficial targeted delivery system. By modifying platelets to express targeting moieties and therapeutic agents, the treatment harnesses the platelet's natural ability to circulate and be cleared by the reticuloendothelial system, directing the therapeutic agent specifically to bone marrow leukemia cells while avoiding systemic toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified platelet-based delivery system effectively targets and eliminates leukemia cells, inducing a potent and durable immune response, reducing the risk of side effects and improving treatment outcomes for AML patients.
Implementation Method 1
the platelet is chemically conjugated to the targeting moiety via copper(I) catalyzed [3+2] azide-alkyne cycloaddition (CuAAC), strain-promoted azide-alkyne cycloaddition (SPAAC), Strain-promoted alkyne-nitrone cycloaddition (SPANC), or Dibenzocyclooctyl (DBCO) Copper-Free cycloaddition
Data Source
AI summary
Disclosed are therapeutic agent delivery vehicle comprising a modified platelet comprising a therapeutic agent cargo and a targeting moiety and methods for treating cancer comprising administering the same to a subject.